Literature DB >> 18367020

Does it matter how we lower blood pressure in obese hypertensive patients?

Arya M Sharma.   

Abstract

Entities:  

Year:  2008        PMID： 18367020     DOI： 10.1007/s11906-008-0004-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

Review 1.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

Authors:  Raj S Padwal; Sumit R Majumdar
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 2.  Antihypertensive agents, insulin sensitivity, and new-onset diabetes.

Authors:  Pantelis A Sarafidis; Samy I McFarlane; George L Bakris
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

3.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry Aj Struijker Boudier; Alberto Zanchetti
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

4.  Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention.

Authors:  S Bérubé-Parent; D Prud'homme; S St-Pierre; E Doucet; A Tremblay
Journal:  Int J Obes Relat Metab Disord       Date:  2001-08

5.  Secular trends in cardiovascular disease risk factors according to body mass index in US adults.

Authors:  Edward W Gregg; Yiling J Cheng; Betsy L Cadwell; Giuseppina Imperatore; Desmond E Williams; Katherine M Flegal; K M Venkat Narayan; David F Williamson
Journal:  JAMA       Date:  2005-04-20       Impact factor: 56.272

6.  Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.

Authors:  Jürgen Scholze; Elmar Grimm; Dana Herrmann; Thomas Unger; Ulrich Kintscher
Journal:  Circulation       Date:  2007-04-02       Impact factor: 29.690

7.  Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.

Authors:  H O Ersoz; K Ukinc; M Baykan; C Erem; I Durmus; A Hacihasanoglu; M Telatar
Journal:  Int J Obes Relat Metab Disord       Date:  2004-03

Review 8.  Use of beta-blockers in obesity hypertension: potential role of weight gain.

Authors:  T Pischon; A M Sharma
Journal:  Obes Rev       Date:  2001-11       Impact factor: 9.213

9.  The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Authors:  Nadia A Khan; Brenda Hemmelgarn; Raj Padwal; Pierre Larochelle; Jeff L Mahon; Richard Z Lewanczuk; Finlay A McAlister; Simon W Rabkin; Michael D Hill; Ross D Feldman; Ernesto L Schiffrin; Norman R C Campbell; Alexander G Logan; Malcolm Arnold; Gordon Moe; Tavis S Campbell; Alain Milot; James A Stone; Charlotte Jones; Lawrence A Leiter; Richard I Ogilvie; Robert J Herman; Pavel Hamet; George Fodor; George Carruthers; Bruce Culleton; Kevin D Burns; Marcel Ruzicka; Jacques deChamplain; George Pylypchuk; Norm Gledhill; Robert Petrella; Jean-Martin Boulanger; Luc Trudeau; Robert A Hegele; Vincent Woo; Phil McFarlane; Rhian M Touyz; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2007-05-15       Impact factor: 5.223
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.